PMID- 9586615
OWN - NLM
STAT- MEDLINE
DCOM- 19980603
LR  - 20190714
IS  - 0090-4295 (Print)
IS  - 0090-4295 (Linking)
VI  - 51
IP  - 4
DP  - 1998 Apr
TI  - A controlled trial of levofloxacin and lomefloxacin in the treatment of 
      complicated urinary tract infection.
PG  - 610-5
AB  - OBJECTIVES: The efficacy and safety of levofloxacin and lomefloxacin in 
      complicated urinary tract infections (UTIs) were compared in a randomized, 
      open-label, multicenter study. METHODS: Outpatients were randomized to receive 
      levofloxacin (250 mg once daily) for 7 to 10 days or lomefloxacin (400 mg once 
      daily) for 14 days. Three hundred thirty-six patients (171 with levofloxacin, 165 
      with lomefloxacin) were evaluable for microbiologic efficacy, and 461 patients 
      (232 with levofloxacin, 229 with lomefloxacin) for safety. RESULTS: The overall 
      microbiologic eradication rate of pathogens was 95.5% (168 of 176) for 
      levofloxacin and 91.7% (154 of 168) for lomefloxacin. Eradication rates with 
      respect to patients were 95.3% (163 of 171) and 92.1% (152 of 165) for 
      levofloxacin and lomefloxacin, respectively. At the 5 to 9-day post-therapy 
      visit, symptoms were completely resolved in 84.8% of levofloxacin-treated 
      patients and were decreased in 8.2% (93.0% clinical success). Among the 
      lomefloxacin-treated patients, complete resolution was seen in 82.4%, with 
      decreased symptoms in 6.1% (88.5% clinical success). Drug-related adverse events 
      (AEs) were reported by 10 (2.6%) and 18 (5.2%) levofloxacin- and 
      lomefloxacin-treated patients, respectively. Compared with levofloxacin-treated 
      patients, more lomefloxacin-treated patients experienced photosensitivity 
      reactions (3 [1.3%] versus 0) and dizziness (2 [0.9%] versus 0). Nausea (3 [1.3%] 
      versus 1 [0.4%]) was more frequent in the levofloxacin-treated group. Six 
      patients in each treatment group had a gastrointestinal AE (1.7%); rash was 
      reported more frequently with lomefloxacin (4 patients [0.4%]) than with 
      levofloxacin (1 patient [0.4%]). Discontinuation because of AEs was observed in 8 
      (3.4%) levofloxacin- and 14 (6.1%) lomefloxacin-treated patients. CONCLUSIONS: 
      Once-daily levofloxacin is as effective as and has a superior tolerability 
      profile than lomefloxacin in the treatment of complicated UTIs.
FAU - Klimberg, I W
AU  - Klimberg IW
AD  - Urology Center of Florida, Ocala 34474, USA.
FAU - Cox, C E 2nd
AU  - Cox CE 2nd
FAU - Fowler, C L
AU  - Fowler CL
FAU - King, W
AU  - King W
FAU - Kim, S S
AU  - Kim SS
FAU - Callery-D'Amico, S
AU  - Callery-D'Amico S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Anti-Infective Agents, Urinary)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolones)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - A4P49JAZ9H (Ofloxacin)
RN  - L6BR2WJD8V (lomefloxacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Infective Agents/*therapeutic use
MH  - Anti-Infective Agents, Urinary/*therapeutic use
MH  - Female
MH  - *Fluoroquinolones
MH  - Humans
MH  - *Levofloxacin
MH  - Male
MH  - Middle Aged
MH  - Ofloxacin/*therapeutic use
MH  - Quinolones/*therapeutic use
MH  - Urinary Tract Infections/complications/*drug therapy
EDAT- 1998/05/20 02:04
MHDA- 2001/03/28 10:01
CRDT- 1998/05/20 02:04
PHST- 1998/05/20 02:04 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1998/05/20 02:04 [entrez]
AID - S0090-4295(97)00708-5 [pii]
AID - 10.1016/s0090-4295(97)00708-5 [doi]
PST - ppublish
SO  - Urology. 1998 Apr;51(4):610-5. doi: 10.1016/s0090-4295(97)00708-5.